Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CCNH | P51946 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL28821795 | 0.97 | MAPK9 (0.46) | MAPK9MAPK10SMN1; SMN2LMNAGAA | |
| SCHEMBL10035798 | 0.93 | MAPK9 (0.51) | MAPK9MAPK10SMN1; SMN2LMNAGAA | |
| SCHEMBL528245 | 0.87 | MAPK9 (0.54) | MAPK9MAPK10SMN1; SMN2KDRCYP1A2 | |
| Benzene SCHEMBL27839441 | 0.87 | MAPK9 (0.54) | MAPK9MAPK10SMN1; SMN2KDRCYP1A2 | |
| SCHEMBL28855220 | 0.86 | MAPK9 (0.51) | MAPK9MAPK10KDREGFRPLK2 | |
| Hydrochloric Acid SCHEMBL27683877 | 0.85 | MAPK9 (0.53) | MAPK9MAPK10SMN1; SMN2KDRCYP1A2 | |
| SCHEMBL5791933 | 0.85 | EGFR (0.45) | MAPK9MAPK10SMN1; SMN2LMNAGAA | |
| SCHEMBL1052342 | 0.85 | EGFR (0.45) | MAPK9MAPK10SMN1; SMN2LMNAGAA | |
| SCHEMBL11091622 | 0.84 | KDR (0.51) | MAPK9MAPK10SMN1; SMN2GAAMEN1 | |
| SCHEMBL19219071 | 0.83 | MAPK9 (0.63) | MAPK9MAPK10SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11498920-B2 | 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors | MASARYKOVA UNIVERZITA (CZ) | 2022-11-15 | — | — | US | disclosed |
| CN-103596957-B | Imidazopyridazines as AKT kinase inhibitors | 拜耳知识产权有限责任公司 | 2016-12-07 | — | — | CN | disclosed |
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | Elan Corporation, Inc. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2516441-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | MAPK9 519/4885MAPK10 686/4885SMN1; SMN2 1174/4885 |
| US-11498920-B2 | 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors | MALT1, BCL3, MCL1 | MAPK9 2973/4885MAPK10 3096/4885SMN1; SMN2 2289/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | MAPK9 519/4885MAPK10 686/4885SMN1; SMN2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.